What do systematic reviews say?

Fewer vs more courses of chemotherapy (with or without radiotherapy

Fewer showed no clear difference in secondary malignant neoplasms compared with more courses of chemotherapy (with or without radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 1.1 [0.74, 1.62]
  3 studies · 2403 participants
  Moderate

Fewer vs more courses of chemotherapy (with or without radiotherapy

Fewer showed no clear difference in death compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.99 [0.73, 1.34]
  3 studies · 2403 participants
  High

Fewer vs more courses of chemotherapy (with or without radiotherapy

Fewer showed no clear difference in progression/relapse compared with more courses of chemotherapy (with or without radiotherapy (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 1.15 [0.91, 1.45]
  3 studies · 2403 participants
  High

Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy

Dose‐intensified chemotherapy showed no clear difference in secondary malignant neoplasms compared with ABVD‐like chemotherapy (with or without radiotherapy (low certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 1.37 [0.89, 2.1]
  7 studies · 2996 participants
  Low

Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy

Dose‐intensified chemotherapy showed no clear difference in death compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.85 [0.7, 1.04]
  7 studies · 2996 participants
  Moderate

Dose‐intensified chemotherapy vs ABVD‐like chemotherapy (with or without radiotherapy

Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.82 [0.7, 0.95]
  7 studies · 2996 participants
  Moderate

Chemotherapy alone vs same chemotherapy plus radiotherapy

Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.71 [0.46, 1.11]
  3 studies · 1011 participants
  Moderate

Chemotherapy alone vs same chemotherapy plus radiotherapy

Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 1.31 [0.99, 1.73]
  3 studies · 1011 participants
  Moderate

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Chemotherapy plus involved‐field radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus extended‐field radiation (low certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 0.86 [0.64, 1.16]
  4 studies · 2397 participants
  Low

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.89 [0.7, 1.12]
  4 studies · 2397 participants
  High

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.99 [0.81, 1.21]
  4 studies · 2397 participants
  High

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 1.03 [0.71, 1.5]
  3 studies · 2962 participants
  Low

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.91 [0.65, 1.28]
  3 studies · 2962 participants
  High

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 1.2 [0.97, 1.48]
  3 studies · 2962 participants
  High

Antihypertensive pharmacotherapy vs control

Antihypertensive pharmacotherapy showed no clear difference in sudden cardiac death ( compared with control (moderate certainty).

• Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals 2016 · Cochrane Headline outcomes only
  RR 0.96 [0.81, 1.15]
  15 studies · 39908 participants
  Moderate

Antihypertensive pharmacotherapy vs control

Antihypertensive pharmacotherapy probably leads to lower non‐fatal myocardial infarction ( compared with control (moderate certainty).

• Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals 2016 · Cochrane Headline outcomes only
  RR 0.85 [0.74, 0.98]
  15 studies · 39908 participants
  Moderate

Antihypertensive pharmacotherapy vs control

Antihypertensive pharmacotherapy probably leads to lower fatal myocardial infarction ( compared with control (moderate certainty).

• Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals 2016 · Cochrane Headline outcomes only
  RR 0.75 [0.62, 0.9]
  15 studies · 39908 participants
  Moderate

Intervention not reported

• Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1007 participants
  Low

Intervention not reported

• Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1007 participants
  Low

Intervention not reported

• Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension 2015 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 977 participants
  Low